ITCES to Conduct Study of Weight Loss Drug Product, Obestrin®
ITCES Corporation has been contracted to perform both recruitment and subsequent statistical meta-analysis in a study of the weight loss drug product, Obestrin®. Obestrin® is the commercial name for the combination drug product formerly designated, AVT-12. Obestrin® functions in part... - March 10, 2010
ITCES Renames AVT-12 Weight Loss Combination Drug Product, Obestrin®
After a successful performance in the recently concluded year-long efficacy controlled trial, AVT-12, a combination drug product intended for weight loss, has been redesignated Obestrin® in preparation for the marketplace. The name Obestrin® is particularly appropriate, given the new... - March 07, 2010
ITCES Corporation Releases Results of Year-Long AVT-12 Weight Loss Controlled Trial
One-year Findings from Controlled Trial of AVT-12 Combination Drug Product on Weight Loss and Various Metabolic Risk Factors - March 06, 2010
AVT-12 Weight Loss Drug Product Study Concludes
The weight loss combination drug product, AVT-12 has most recently been the subject of a year-long phase III randomized, double-blind, placebo-controlled efficacy trial, conducted by ITCES Corporation. - March 05, 2010
ITCES Innovator of the Year Award Presented
The ITCES Innovator of the Year Award 2009 has been presented to Dr. David Klein for his recent work in unified algorithmic theory. ITCES Director, Thomas Schwartz made the award presentation. “It is my honor to present the 2009 ITCES Innovator of the Year Award to Dr. David Klein. Our... - March 03, 2010